Targeting HER3 in EGFR-Mutant NSCLC
Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.
EP: 1.Overview of Antibody Drug Conjugates in Lung Cancer
EP: 2.ADCs in Development for the Treatment of Lung Cancer
EP: 3.Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
EP: 4.HER2-Directed Agents in NSCLC
Now Viewing
EP: 5.Targeting HER3 in EGFR-Mutant NSCLC
EP: 6.Exploring TROP2 Expression in Patients with NSCLC
Related Videos
Related Content
